 SHANGHAI and SAN FRANCISCO, May 24, 2021 GLOBE NEWSWIRE -- Zai Lab Limited NASDAQ: ZLAB; HKEX: 9688, an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Zais partner NovoCure Limited NASDAQ: NVCR to study radiosurgery plus Tumor Treating Fields TTFields compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer NSCLC. 